BRVE · Braveheart Bio Inc. Common Stock
View on chartInsiders & Stakes
| AH Bio Fund IV, L.P. | ▲ Buy | Open Market | 10,232,420 Shares held | 8/7/2026 | View profile |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | ▲ Buy | Open Market | 10,185,478 Shares held | 8/7/2026 | View profile |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% Owner | ▼ Sell | Other | 7,420,091 Shares held | 8/7/2026 | View profile |
| Murdoch Travis CEO and President | ▲ Buy | Open Market | 2,940,670 Shares held | 8/7/2026 | View profile |
| Christopher Viehbacher President and CEO | ▲ Buy | Open Market | 609,519 Shares held | 8/7/2026 | View profile |
| Malek David I Director | ▲ Buy | Open Market | 533,845 Shares held | 8/7/2026 | View profile |
| Rickey James Paul Chief Financial Officer | ▲ Buy | Open Market | 520,927 Shares held | 8/7/2026 | View profile |
| Anderson Michele A. Chief Development Officer | ▲ Buy | Open Market | 332,161 Shares held | 8/7/2026 | View profile |
| ORBIMED ADVISORS LLC Director | ▲ Buy | Open Market | 273,333 Shares held | 8/7/2026 | View profile |
| Chimovits Erez Director | ▲ Buy | Open Market | 273,333 Shares held | 8/7/2026 | View profile |
| David Charles Lubner | ▲ Buy | Open Market | 55,555 Shares held | 8/7/2026 | View profile |
Transaction History
| Chimovits Erez | ▲ Buy | Open Market | 1,666,667 | $30.0M | 8/7/2026 |
| Chimovits Erez | ▲ Buy | Open Market | 273,333 | $4.9M | 8/7/2026 |
| ORBIMED ADVISORS LLC | ▼ Sell | Other | 9,132,420 | — | 8/7/2026 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 1,666,667 | $30.0M | 8/7/2026 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 273,333 | $4.9M | 8/7/2026 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | ▼ Sell | Other | 9,132,420 | $0 | 8/7/2026 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | ▼ Sell | Other | 7,990,867 | $0 | 8/7/2026 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | ▲ Buy | Open Market | 1,920,000 | $34.6M | 8/7/2026 |
| Murdoch Travis | ▲ Buy | Open Market | 83,333 | $1.5M | 8/7/2026 |
| David Charles Lubner | ▲ Buy | Open Market | 55,555 | $1000K | 8/7/2026 |
| Chimovits Erez | ▼ Sell | Other | 9,132,420 | — | 8/7/2026 |
| AH Bio Fund IV, L.P. | ▼ Sell | Other | 9,132,420 | — | 8/7/2026 |
| AH Bio Fund IV, L.P. | ▲ Buy | Open Market | 1,100,000 | $19.8M | 8/7/2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ▼ Sell | Other | 7,420,091 | — | 8/7/2026 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | ▲ Buy | Open Market | 1,680,000 | $30.2M | 8/7/2026 |
| Rickey James Paul | ▲ Buy | Open Market | 27,777 | $500K | 8/7/2026 |
| Christopher Viehbacher | ▲ Buy | Open Market | 83,333 | $1.5M | 8/7/2026 |
| Malek David I | ▲ Buy | Open Market | 4,166 | $75K | 8/7/2026 |
| Anderson Michele A. | ▲ Buy | Open Market | 1,111 | $20K | 8/7/2026 |